Skip to main content
VCbacked
Log inGet Started

Parabilis Medicines

Cambridge, United States

Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.

$305.0M raised
Jan 2026
Series F
BiopharmaBiotechnologyHealth CareLife ScienceMedical

Top Investors

General CatalystRA Capital ManagementARCH Venture PartnersCormorant Asset ManagementCatalio Capital Management

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Parabilis Medicines

How much funding has Parabilis Medicines raised?
Parabilis Medicines has raised $305.0M in total funding. The most recent round was Series F. The last funding was announced in January 2026.
Who are Parabilis Medicines's investors?
Parabilis Medicines's investors include General Catalyst, RA Capital Management, ARCH Venture Partners, Cormorant Asset Management, Catalio Capital Management.
Where is Parabilis Medicines headquartered?
Parabilis Medicines is headquartered in Cambridge, United States.
What does Parabilis Medicines do?
Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.
What stage is Parabilis Medicines at?
Parabilis Medicines is at the Series F stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Parabilis Medicines — Funding & Investors." VCBacked, January 8, 2026, https://www.vcbacked.co/company/parabilis-medicines. Accessed June 3, 2026.
APA
VCBacked. (2026). Parabilis Medicines — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/parabilis-medicines
Wikipedia (cite web)
{{cite web |title=Parabilis Medicines — Funding & Investors |url=https://www.vcbacked.co/company/parabilis-medicines |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biopharma

View all
ParcelBio
San Francisco$13.2M
Modicus Prime
Austin
Latus Bio
Philadelphia
Ocugen
Malvern
Ember LifeSciences
Los Angeles$16.5M
ClearNote Health
San Diego